




RealRate

PHARMACEUTICAL 2014

Statera Biopharma Inc
Rank 191 of 234



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of Statera Biopharma Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Statera Biopharma Inc compared to the market average is the variable Other Net Income, increasing the Economic Capital Ratio by 24% points. The greatest weakness of Statera Biopharma Inc is the variable Stockholders Equity, reducing the Economic Capital Ratio by 118% points.

The company's Economic Capital Ratio, given in the ranking table, is 128%, being 115% points below the market average of 243%.

Input Variable	Value in 1000 USD
Assets, Current	11,157
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	5,986
Liabilities, Non-Current	0
Other Assets	3,081
Other Compr. Net Income	2,627
Other Expenses	0
Other Liabilities	7,129
Other Net Income	11,435
Other Revenues	0
Property and Equipment	458
Research and Development	19,526
Selling, General and Administrative Expense	12,039

Output Variable	Value in 1000 USD
Assets	14,696
Liabilities	13,115
Expenses	31,565
Revenues	0
Stockholders Equity	1,581
Net Income	-20,129
Comprehensive Net Income	-18,816
BaseVar	36,719
ECR before LimitedLiability	-111%
Economic Capital Ratio	128%